Antimalarial Quinolines with Reduced Gap Junction Inhibitory Activity
Reference Number: 06-23
Inventors: Duy Hua, Dolores Takemoto, and Peter Chiang
This technology has a number of compounds containing quinoline moiety that reduce specific gap junction (such as connexins 50) inhibitors for the studies of various neutral effects. The link has been discovered to be that mefloquine and its analogs inhibit gap junctions, which are responsible for neutron transmission. The present invention also contains anti-malarial capabilities that are different from most other agents. Most anti-malarial agents such as mefloquine have serious side effects such as depression and psychotic or suicidal episodes. The present invention does not have these effects.
- Treatment of diseases related to gap junctions
- The studying of neural degenerative and psychological diseases
- Potent specific gap junction inhibitors can be used to treat ischemic injury such as heart surgery, strokes or retinal surgery
- For use in the finding of drugs with anti malarial activity
The specific Cx50 gap junction inhibitor, PQ1, and its analogs can be used to study neural degenerative diseases such as Parkinson’s. There were less psychological effects found in the application of the anti malarial drugs than other alternatives. There is a large market for the anti malarial drugs in military personnel as well as civilian travelers.
- U.S. patent #8,809,368 issued on August 19, 2014.
Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Interested parties should contact:
Kansas State University Institute for Commercialization (KSU-IC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909